ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Merritt To Head Nursing Center’s Implementation; Nurse Research And Training Opportunities Varied

January 10, 1986

Contract For NCI CIS Service Center Awarded To Fred Hutchinson

December 11, 2009

ACS Encourages Grant Applications In All Aspects Of Pain Control

May 7, 1993

Highlights of NCDDGs: 3 Drugs on Market, 12 in Development; Advisors Approve Plan to Issue $10.5 Million Contract For Pediatric Preclinical Testing Program

November 29, 2002

CALG Loses Pediatrics Grant

July 20, 1979

Reports On AACR Scientific Sessions

May 21, 1976